CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 27 enrolled
Drug / intervention
Dulaglutide (Reference) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03363906
NCT03363906Phase 1Completed

Relative Bioavailability of an Investigational Single Dose of Dulaglutide After Subcutaneous Administration by a Single Dose Pen Compared to a Prefilled Syringe in Healthy Subjects

Eli Lilly and Company·interventional·Posted Dec 6, 2017·Updated Jul 29, 2019

In Brief

A Phase 1 clinical trial evaluating Dulaglutide (Reference) and Dulaglutide (Test) for Healthy. Completed, enrolled 27 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate a new formulation of dulaglutide (study drug) administered under the skin as one injection using a single dose pen compared to three injections using a pre filled syringe. This study will evaluate how much of the study drug enters the body and how long it takes the body to get rid of it. Information about any side effects that may occur will also be collected. The study will last about 84 days, including screening and will require overnight stays in the clinical research unit (CRU).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedDec 6, 2017
Enrollment StartDec 7, 2017
Primary CompletionJun 6, 2018
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 8.6 years ago

Interventions

Dulaglutide (Reference)drug

Administered SC

Dulaglutide (Test)drug

Administered SC